Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Sep;10(9):513-21.
doi: 10.1038/nrurol.2013.143. Epub 2013 Jul 2.

Neuromodulation for overactive bladder

Affiliations
Review

Neuromodulation for overactive bladder

Jamie Bartley et al. Nat Rev Urol. 2013 Sep.

Abstract

Overactive bladder (OAB) affects millions of people worldwide yet first-line treatments are often poorly tolerated and compliance rates are low. Neuromodulation works via afferent nerve modulation and offers a minimally invasive and reversible alternative treatment option for patients with OAB who have failed first-line therapy. Neuromodulation has revolutionized the management of OAB and is now well established as a safe and effective treatment for those refractory to conservative treatments. Multiple neuroanatomical pathways have been described for sacral neuromodulation including the S3 nerve root, pudendal nerve and tibial nerve. The S3 nerve root is currently the main treatment target and has the most long-term data on safety and efficacy to support its use. However, studies on neuromodulation at the pudendal nerve or posterior tibial nerve have been positive and their role in treatment continues to evolve. Most urologists who are experienced in voiding dysfunction can become proficient in each technique. Patient selection, surgical techniques and postoperative management differ slightly between approaches and urologists should familiarize themselves with these differences. Treatment of OAB should progress from the least to most invasive modality, and neuromodulation provides an attractive option owing to its minimally invasive approach, tolerability, positive outcomes and reversibility.

PubMed Disclaimer

References

    1. Urology. 1984 Jan;23(1):97-100 - PubMed
    1. J Urol. 2011 Mar;185(3):981-6 - PubMed
    1. Value Health. 2005 Jul-Aug;8(4):495-505 - PubMed
    1. Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429 - PubMed
    1. J Urol. 2007 Nov;178(5):2029-34 - PubMed

MeSH terms

Substances